Olomoucine II, New Effective CDK Inhibitor with Strong Cytotoxic Properties

Olomoucine II, New Effective CDK Inhibitor with Strong Cytotoxic Properties

Saved in:

Bibliographic Details
Main Authors:	R. Lenobel, L. Havli, P.V. Kryscaron, M. Otyepka, M. Strnad
Format:	Article
Language:	English
Published:	Wiley 2001-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1100/tsw.2001.227
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
by: M. Strnad, et al.
Published: (2001-01-01)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
by: M. Strnad, et al.
Published: (2001-01-01)

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
by: Jitka Holcakova, et al.
Published: (2014-01-01)

Identification of new inhibitors of the kinase activity of CDK2 and CDK9 by molecular modeling and high-efficiency screening
by: G.V. Andrianov, et al.
Published: (2021-12-01)

Study of cytostatic and cytotoxic characteristics of modified peptide CDK4/6 inhibitors – functional analogs of p16INK4a (90-97)
by: V. K. Bozhenko, et al.
Published: (2021-01-01)

Initiation of apoptosis by photodynamic therapy on MCF7 cells
by: Hana Kolacaronova, et al.
Published: (2001-01-01)

In silico identification of novel CDK4 inhibitors for retinoblastoma
by: Mukesh kumar, et al.
Published: (2024-12-01)

Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights
by: Wagdy M. Eldehna, et al.
Published: (2022-12-01)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2021-03-01)

Modeling the impact of CDK4 / 6 inhibitors on reducing cancer mortality
by: N. A. Avxentyev, et al.
Published: (2025-05-01)

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
by: Mohammed Hawash
Published: (2024-10-01)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
by: Efthymia Skafida, et al.
Published: (2023-01-01)

An immunological mechanism of resistance to CDK4/6 inhibitors in HR+ breast cancer
by: Claudia Galassi, et al.
Published: (2025-12-01)

CDK4/6 inhibitor-associated vortex keratopathy: a case report
by: Lian Shu, et al.
Published: (2025-04-01)

BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
by: Hana Paculová, et al.
Published: (2017-10-01)

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2025-02-01)

Global trends and topics in CDK7 inhibitor research: a bibliometric analysis
by: Jiamin Liu, et al.
Published: (2024-09-01)

Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors
by: Jinming Yang, et al.
Published: (2025-08-01)

Targeting CDK4/6 in Cancer: Molecular Docking and Cytotoxic Evaluation of <i>Thottea siliquosa</i> Root Extract
by: Maruthamuthu Rathinam Elakkiya, et al.
Published: (2025-07-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
by: Alireza Azimi, et al.
Published: (2018-03-01)

Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
by: LI Bin, TAO Zhonghua, HU Xichun
Published: (2025-03-01)

Thiazolo-pyridopyrimidines: An in silico evaluation as a lead for CDK4/6 inhibition, synthesis and cytotoxicity screening against breast cancer cell lines
by: Chaithra R Shetty, et al.
Published: (2024-07-01)

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib
by: David Cabezas, et al.
Published: (2025-06-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment
by: Tong Gao, et al.
Published: (2025-05-01)

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
by: Yesid Alvarado-Valero, et al.
Published: (2025-08-01)

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer
by: Hyunwook Kim, et al.
Published: (2025-02-01)

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)
by: Md Mohiuddin, et al.
Published: (2025-08-01)

Targeting CDK2 for cancer therapy
by: Erik S. Knudsen, et al.
Published: (2025-08-01)

Properties of new polycationic bacteriochlorin photosensitizers: cytotoxicity and interaction with biofilms
by: Irina Tiganova, et al.
Published: (2024-09-01)

Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat
by: Stefan Senekowitsch, et al.
Published: (2025-03-01)

The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i
by: Mohamed Khalifa, et al.
Published: (2025-04-01)

A translational journey into resistance: decoding the role of NF1 in CDK4/6-inhibitor failure
by: Francesco Schettini, et al.
Published: (2025-08-01)

Identification and evaluation of pyrimidine based CDK6 inhibitors against glioblastoma using integrated computational approaches
by: Hina Manzoor, et al.
Published: (2025-07-01)

Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer
by: Marya Hussain, et al.
Published: (2025-03-01)

Synthesis, Cytotoxic Activity, and DNA Binding Properties of Copper (II) Complexes with Hesperetin, Naringenin, and Apigenin
by: Mingxiong Tan, et al.
Published: (2009-01-01)

CDK1 mediates the metabolic regulation of DNA double-strand break repair in metaphase II oocytes
by: Tian-Jin Xia, et al.
Published: (2025-02-01)